Instapath provides digital imaging tools for rapid on-site pathology evaluation to repeat biopsy procedures and increase hospital revenue.
Over 7 million Americans need biopsy procedures every year, costing over $8 billion; 20% of procedures fail to render an accurate diagnosis. Over 1 million patients have to go through costly, painful repeat biopsy procedures. Instapath makes digital microscopic imaging devices that improve rapid on-site evaluation (ROSE) of biopsies, reducing the need for repeat procedures and increasing operating room capacity and hospital revenue.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 9, 2021 | Grant | $1M | 1 |
National Science Foundation
|
— | Detail |
| Jun 29, 2018 | Grant | $225K | 1 |
National Science Foundation
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Science Foundation
|
Yes | Grant |